COVID-19 Patients with Cancer Advised to Identify Interactions with Anti-cancer Medications
Breast cancer patients are at high risk of contracting COVID-19 (coronavirus) disease. This is evident since both cancer and its treatment tend to weaken the immune system, resulting in complications arising from COVID-19. Hence, companies in the paclitaxel injection market are boosting their output capacities to avoid supply chain jolts in the healthcare industry. As such, patients who are not actively receiving cancer treatment are also at a risk of contracting COVID-19, since the effects of the treatment are usually long lasting. Thus, companies in the paclitaxel injection market are capitalizing on such value-grab opportunities in order to keep economies running during the ongoing pandemic.
Healthcare associations are advising cancer patients to maintain adequate delivery of medications and supplies that last for collective weeks. COVID-19 patients with breast cancer are being advised to identify any interactions with anti-cancer medications.
Cremophor and Albumin-free Formulations in Paclitaxel Injections Gain Market Recognition
Albumin-free formulations in paclitaxel injections are being preferred by clinicians to improve medical outcomes. In December 2019, Mumbai-based Sun Pharma Advanced Research Company Ltd. (SPARC)— a clinical stage bio-pharmaceutical company announced that Abraxis Bioscience LLC has withdrawn its infringement claims over the former’s Paclitaxel Injection Concentrate for Suspension (PICS). Innovative product offerings are contributing toward the growth of the paclitaxel injection market. Moreover, regulatory approvals for products are bolstering the credibility credentials of manufacturers, thus paving the way for successful launch.
Cremophor® and albumin-free formulations hold promising potentials for companies in the paclitaxel injection market. Such innovative formulations are expected to boost productivity levels in hospitals, as clinicians can easily use PVC (Poly Vinyl Chloride) or non-PVC sterile infusion bags for drug delivery. Cremophor® and albumin-free formulations are expected to eliminate the need for premedication to prevent hypersensitivity.
Superior Paclitaxel Nanotechnology-driven Formulations Fuel Development of New Drugs
The paclitaxel injection market has transitioned from the use of anti-cancer drug Taxol® to incorporate Abraxane®, a human albumin-based preparation of paclitaxel. Superior paclitaxel nanotechnology-driven formulations are sparking competition among pharma companies. However, these formulations need to undergo rigorous regulatory processes, clinical evaluations, and patentability tests before launch. These factors are inhibiting the growth of the paclitaxel injection market. Hence, pharma companies should focus on new drug development with the help of R&D.
Pharma companies are increasing efforts to create availability for safe and effective drug therapies for patient satisfaction with the help of nano paclitaxel formulations. Combination therapies involving paclitaxel and doxorubicin (DOX) are being highly publicized in the healthcare landscape. These therapies are widely used in clinical practice improve anti-cancer effect of drugs and minimize adverse events.
Nanoparticle Formulations Help Improve Efficacy of Gemcitabine Chemotherapy
Pancreatic cancer is of the most lethal diseases with a poor survival rate. Such medical conditions are fueling innovations in paclitaxel injections. Gemcitabine (GEM) is considered as the gold standard for chemotherapy among pancreatic cancer patients. However, GEM-acquired resistance in cancer cells is acting as a major setback for its continued implementation. Hence, companies in the paclitaxel injection market are capitalizing on this opportunity to innovate in unique paclitaxel–poly (lactic-co-glycolic acid) (PLGA) nanoparticles (PPNPs) formulations to improve patient outcomes.
Nanoparticle formulations help to target lipid metabolism and improve efficacy of gemcitabine chemotherapy. Companies in the paclitaxel injection market are increasing their production capabilities in nanoparticle formulations to inhibit excessive lipid formulation and alter membrane stability. This molecular action is improving the efficacy of gemcitabine chemotherapy, owing to evidences of enhanced inhibitory effects on the tumorigenic assays in pancreatic cancer cells.
Biocompatible PEG Holds Promising Potentials in Nanotherapeutic Strategies
Nanotherapeutic strategies have become a recurring trend in the paclitaxel injection market. Paclitaxel-conjugated nanofibers split into tiny nanoparticles inside the body. It is emerging as a new strategy for anticancer therapy. Nanoparticles can be loaded with therapeutic agents and later injected in the body to administer drugs safely and with greater efficacy. Such treatment methods are reducing incidence of side effects usually common in cancer treatments. Companies in the paclitaxel injection market should collaborate with researchers from renowned universities to develop nanoparticles that remain stable in the blood to allow efficacious circulation of drug formulations in order to reach its target.
Companies are increasing focus in nanocarriers that are biocompatible. Stable nanofibers with good loading capacities are in high demand. Extensively used biodegradable and biocompatible pharmaceutical ingredients such as polyethylene glycol (PEG) hold promising potentials in nanofiber development.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.